NASDAQ: AZRX

SEARCH

SIGN UP

AzurRx Logo
  • About
      • Back
      • Company Profile
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
  • Science & Technology
      • Back
      • Overview
      • Programs
      • Development Pipeline
      • Cystic Fibrosis
      • Chronic Pancreatitis
      • Immune Checkpoint Inhibitor Colitis
      • COVID-19 GI Infections
      • Non-Systemic Biologics
      • Digestive Enzymes
      • Niclosamide
  • Investors
      • Back
      • Press Releases
          • Back
          • 2021
          • 2020
          • 2019
          • 2018
          • 2017
          • 2016
          • 2015
          • 2014
      • Events
      • Presentations
      • Regulatory Filings
      • Financial Statements
          • Back
          • 2020
              • Back
              • Q2 2020
              • Q1 2020
          • 2019
              • Back
              • Q4 2019
              • Q3 2019
              • Q2 2019
              • Q1 2019
          • 2018
              • Back
              • Q4 2018
              • Q3 2018
              • Q2 2018
              • Q1 2018
          • 2017
              • Back
              • Q4 2017
              • Q3 2017
              • Q2 2017
              • Q1 2017
          • 2016
              • Back
              • Q4 2016
              • Q3 2016
      • Stock Info
      • Analyst Coverage
      • Corporate Governance
      • Contact Us
  • News and Media
      • Back
      • Podcasts
      • Media Interviews
  • Clinical Trials
      • Back
      • Ongoing Clinical Trials
      • Completed Clinical Trials
      • Clinical Publications
  • Collaborations
      • Back
      • Partnering with AzurRx
  • Contact
      • Back
      • Contact Us
      • Subscribe
  • Home
  • Investors
  • Press Releases
  • 2020

Menu

  • Press Releases
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
  • Events
  • Presentations
  • Regulatory Filings
  • Financial Statements
    • 2020
      • Q2 2020
      • Q1 2020
    • 2019
      • Q4 2019
      • Q3 2019
      • Q2 2019
      • Q1 2019
    • 2018
      • Q4 2018
      • Q3 2018
      • Q2 2018
      • Q1 2018
    • 2017
      • Q4 2017
      • Q3 2017
      • Q2 2017
      • Q1 2017
    • 2016
      • Q4 2016
      • Q3 2016
  • Stock Info
  • Analyst Coverage
  • Corporate Governance
  • Contact Us

2020 News

Filters
List of articles in category 2020 News
Title Date
AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency 30 Nov, 2020
AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients 17 Nov, 2020
AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production 10 Nov, 2020
AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic Alternatives 29 Oct, 2020
AzurRx BioPharma Announces Formation of Scientific Advisory Board 21 Oct, 2020
AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis 14 Oct, 2020
AzurRx BioPharma CEO Issues Letter to Shareholders 07 Oct, 2020
AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference 15 Sep, 2020
AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4) 31 Aug, 2020
AzurRx BioPharma to Present at The LD 500 Virtual Conference (September 4th) 18 Aug, 2020
AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis 17 Aug, 2020
AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis 13 Aug, 2020
AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders 12 Aug, 2020
AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency 11 Aug, 2020
AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis – with First Patient Screened and Three Clinical Trial Sites Activated 22 Jul, 2020
AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange 20 Jul, 2020
AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product 07 May, 2020
AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit) 05 May, 2020
AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis 30 Apr, 2020
AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites 29 Apr, 2020
AzurRx BioPharma Issues Letter to Shareholders 21 Apr, 2020
Argus Research Initiates Equity Research Report Coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX) 20 Apr, 2020
AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product 16 Apr, 2020
AzurRx BioPharma to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020 15 Apr, 2020
AzurRx Appoints Gregory Oakes to its Board of Directors 09 Apr, 2020
AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit) 01 Apr, 2020
AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th 18 Mar, 2020
AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit) 02 Mar, 2020
AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference 18 Feb, 2020
AzurRx BioPharma Announces Closing of $6.9 Million Private Placement 13 Jan, 2020
AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco 10 Jan, 2020
AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th) 06 Jan, 2020
AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer 03 Jan, 2020
  • About
  • Science & Technology
  • Investors
  • News and Media
  • Clinical Trials
  • Collaborations
  • Contact

Contact Us

AzurRx BioPharma, Inc.

1615 South Congress Avenue
Suite 103
Delray Beach, Florida 33445 

Tel: 646-699-7855
info@azurrx.com

AzurRx SAS

Jardin des Entreprises, Bat 1
290, Chemin de Saint-Dionisy
30980 Langlade, France

Tel: +33 (0)4 66 67 08 16

SiteMap Ⓒ 2021 AzurRx All Rights Reserved.